Nuclea Biotechnologies Raises $4.7M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics development firm Nuclea Biotechnologies has closed on a $4.7 million Series B financing round, its President and CEO confirmed to GenomeWeb Daily News.

Patrick Muraca said that the funds will be used for submission of its serum-based fatty acid synthase diagnostic test for prostate cancer to the US Food and Drug Administration for 510(k) clearance. Nuclea anticipates it will submit its application by the end of September, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.